Navigation Links
CIC Closes Financing Round
Date:1/3/2011

Phoenix is a private equity fund that specializes in making concentrated investments in publicly traded companies in North America. Phoenix is co-managed by Philip Sassower, CEO, and Andrea Goren, Managing Director. Mr. Sassower is currently CIC's Chairman and CEO, while Mr. Goren is the Company's Acting CFO.

Forward Looking StatementsCertain statements contained in this press release, including without limitation, statements containing the words "believes", "anticipates", "hopes", "intends", "expects", and other words of similar import, constitute "forward looking" statements within the meaning of the Private Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors, which may cause actual events to differ materially from expectations.  Such factors include the following (1) technological, engineering, quality control or other circumstances which could delay the sale or shipment of products containing the Company's technology; (2) economic, business, market and competitive conditions in the software industry and technological innovations which could affect the Company's business; (3) the Company's inability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others or prevent others from infringing on the proprietary rights of the Company; and (4) general economic and business conditions and the availability of sufficient financing.Contact Information:CICInvestor Relations & Media Inquiries:Andrea Goren+1.650.802.7723agoren@cic.com
'/>"/>

SOURCE Communication Intelligence Corporation (CIC)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology news :

1. Mans closest relationship under strain? New research reveals why chimpanzees attack humans
2. Molecular Biometrics Closes $12.5 Million Series B Equity Funding
3. In the war between the sexes, the one with the closest fungal relationship wins
4. CIC to Raise $2.2 Million in Financing and Announces Changes in Management
5. KINAXO Completes Financing Round to Enhance Biomarker Development
6. EmSense Raises $9 Million Series C Round of Financing
7. PDC Biotech GmbH Announces Close of Series A Financing
8. Pacific Biometrics Completes $4 Million Debt Financing
9. Satellite data provide a new way to monitor groundwater in agricultural regions
10. GEN co-sponsors roundtable discussion on novel bioremediation techniques
11. Can cacti escape underground in high temperatures?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
(Date:1/18/2017)... 2017  In vitro diagnostic (IVD) companies were very ... (M&A), and Kalorama Information expects that trend to continue ... shifting. Generally, uncertainty in reimbursement and healthcare reform in ... changed the acquisitions landscape. Instead of looking to buy ... partners outside of their home country and also to ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
Breaking Biology Technology: